What is PEP-TZP-2, and what is it studied for?
PEP-TZP-2 is a 39-amino-acid synthetic peptide with agonist activity at both the GIP and GLP-1 receptors. It is the reference compound for dual incretin research: how engaging both receptors together affects insulin secretion, appetite signalling and body composition compared with GLP-1 activation alone.
What is the structure of PEP-TZP-2?
The sequence is based on native GIP with modifications that add GLP-1 receptor affinity, a C20 fatty-diacid side chain for albumin binding and a half-life of about five days, and aminoisobutyric acid substitutions that protect it from DPP-4 cleavage. Supplied lyophilized, identity by LC-MS, purity by HPLC-UV on every lot.
| Identifier | Value |
|---|---|
| Molecular formula | C225H348N48O68 |
| Molecular weight | 4813 g/mol |
| Residues | 39 |
| CAS number | 2023788-19-2 |
| PubChem CID | 166567236 |
| Current lot | TIR10-0803 |
How is PEP-TZP-2 thought to work?
GLP-1 receptor activation drives glucose-dependent insulin release and slows gastric emptying; GIP receptor activation potentiates insulin secretion and acts on adipose tissue and on central appetite circuits. The compound is biased toward GIP receptor affinity, and part of the research interest is whether that bias explains the difference from GLP-1-only agonists.
Which research areas use PEP-TZP-2?
| Area | Typical models and endpoints |
|---|---|
| Dual incretin signalling | cAMP and beta-arrestin recruitment assays at each receptor, and the effect of the GIP bias on downstream signalling. |
| Beta-cell function | Insulin secretion and islet models under glucose challenge. |
| Appetite and gastric emptying | Central and gastrointestinal endpoints in rodent models. |
| Comparison with GLP-1-only agonists | Matched-exposure arms against PEP-SMG-1. |
What does the published literature show?
The SURMOUNT-1 trial (Jastreboff and colleagues, New England Journal of Medicine, 2022) reported dose-dependent weight reduction over 72 weeks, and the SURPASS programme established glycaemic results in type 2 diabetes. Mechanistic work on the GIP component continues, including whether GIP receptor agonism or antagonism is the relevant contribution. These are clinical results in regulated trials and are cited here as the context for research interest, not as a description of research use of the material sold on this site.
How is PEP-TZP-2 handled in the laboratory?
Slow to dissolve because of the side chain; add water down the wall, swirl, allow a few minutes. Light-sensitive in solution: carton, 2 to 8°C, 28-day window. The concentration table covers dilution volumes and microlitre aliquots; the storage guide covers stability by compound class.
What does the current certificate show?
Lot TIR10-0803 tested at 99.80% purity by RP-HPLC (214 nm), identity confirmed by LC-MS/MS, endotoxin <0.05 EU/mL. The certificate is in the COA library and the lot number on the vial matches it. Sold as 10 mg per vial at $100, for laboratory research only.
Certificate history for PEP-TZP-2
Every certificate the library holds for this compound, newest first. A replaced lot stays listed so the history can be read; the certificate dataset reads all 114 together.
| Lot | Issued | Size | Identity | Purity | Content | Status |
|---|---|---|---|---|---|---|
| TIR60-0803 | Aug 17, 2026 | 60 mg | LC-MS/MS | 99.79% | 61.11 mg | Current |
| TIR30-0803 | Aug 17, 2026 | 30 mg | LC-MS/MS | 99.85% | 30.69 mg | Current |
| TIR20-0803 | Aug 17, 2026 | 20 mg | LC-MS/MS | 99.80% | 20.77 mg | Current |
| TIR100-0803 | Aug 17, 2026 | 100 mg | LC-MS/MS | 99.85% | 101.88 mg | Current |
| TIR10-0803 | Aug 17, 2026 | 10 mg | LC-MS/MS | 99.80% | 10.18 mg | Current |
| TIR100-0616 | Jun 25, 2026 | 100 mg | MALDI-MS | 99.9% | 101.25 mg | Replaced |
| TIR600-0528 | Jun 17, 2026 | 60 mg | MALDI-MS | 99.9% | 60.57 mg | Replaced |
| TIR20-0528 | Jun 17, 2026 | 20 mg | MALDI-MS | 99.9% | 20.38 mg | Replaced |
| TIR10-0528 | Jun 17, 2026 | 10 mg | MALDI-MS | 99.9% | 10.42 mg | Replaced |
| TIRZ10-0318 | Apr 3, 2026 | 10 mg | MALDI-MS | 99.8% | 11.06 mg | Replaced |
Frequently asked questions
Why is PEP-TZP-2 chosen over PEP-SMG-1 for some studies?
When the question involves the GIP pathway or the interaction between the two incretin receptors, only a dual agonist can test it.
What purity does the current lot report?
99.80% purity by RP-HPLC (214 nm), identity confirmed by LC-MS/MS, content 10.18 mg by HPLC quantitation, endotoxin <0.05 EU/mL, heavy metals <0.01 ppm. Certificate COA7606, issued 17 August 2026 by Bioviridian Inc.
Does PEP-TZP-2 degrade faster than shorter peptides?
No faster in sealed lyophilized form. In solution, follow the 28-day refrigerated window and protect from light.
References
- Jastreboff AM et al. N Engl J Med. 2022.
- Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018.
Clinical results cited above describe regulated trials of pharmaceutical products and are given as context for research interest only. Nothing on this page describes or recommends use of the material sold here in humans or animals.
PEP-TZP-2 10 mg
$100 per vial
Lot TIR10-0803 · 99.80% RP-HPLC (214 nm) · certificate published
View productRelated
- PEP-SMG-1: what the three structural modifications do, and why the salt form on a certificate matters
- PEP-TZP-2 is built on the GIP backbone, not GLP-1, and it is not a balanced dual agonist
- How to verify a certificate of analysis is genuine: eight checks, and one real discrepancy found in this library
- Peptide stability in plasma and serum: how the in-vitro assay is run and what it can honestly predict
- Glossary of certificate terms